Jason J. Rose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jason J. Rose has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Jesús Tejero
Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 15261, USA; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 15261, USA; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, 15260, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA
7 shared publications - Mark T. Gladwin
Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
6 shared publications - Anthony W. DeMartino
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
4 shared publications Mark T. Gladwin
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Maryland School of Medicine, Baltimore, Maryland
4 shared publicationsAlison Morris
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, PA
3 shared publicationsQinzi Xu
3 shared publications
Latest Publications
- 15 October 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Immobilized Neuroglobin Scavenges Carbon Monoxide From Circulating Carboxyhemoglobin
Carbon monoxide (CO) poisoning is responsible for around 50,000 emergency department visits per year in the United States alone. Currently, there is no available antidote for CO poisoning. We have previously developed an antidotal therapy based on an engineered hemeprotein, human neuroglobin (Ngb-H64Q-CCC). Intravenous infusion of Ngb-H64Q-CCC removes CO from circulating red blood cells and improves survival in a lethal CO poisoning mouse model. However, the infusion of heme-containing proteins has inherent heme toxicity risks that may limit the dose that can be used safely without liver or kidney toxicity. To overcome these problems, we have investigated the development of immobilized Ngb in a solid matrix. This approach allows for the development of a CO removal system using an extracorporeal blood-circulating system coupled with a stationary matrix with immobilized Ngb-H64Q-CCC. Such a system avoids drug infusion and possible organ injury, allows for antidote recycling, and provides advantages for storage and handling of the antidote. Here we have developed Ngb-H64Q-CCC covalently bound to N-hydroxysuccinimide agarose. The immobilized protein shows preserved heme redox activity and retains its CO removal capacity after successive regeneration cycles. We expect that this novel approach will advance the development of new scavenger-based therapies for CO poisoning.
- 15 October 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Immobilized Neuroglobin Scavenges Carbon Monoxide From Circulating Carboxyhemoglobin
Carbon monoxide (CO) poisoning is responsible for around 50,000 emergency department visits per year in the United States alone. Currently, there is no available antidote for CO poisoning. We have previously developed an antidotal therapy based on an engineered hemeprotein, human neuroglobin (Ngb-H64Q-CCC). Intravenous infusion of Ngb-H64Q-CCC removes CO from circulating red blood cells and improves survival in a lethal CO poisoning mouse model. However, the infusion of heme-containing proteins has inherent heme toxicity risks that may limit the dose that can be used safely without liver or kidney toxicity. To overcome these problems, we have investigated the development of immobilized Ngb in a solid matrix. This approach allows for the development of a CO removal system using an extracorporeal blood-circulating system coupled with a stationary matrix with immobilized Ngb-H64Q-CCC. Such a system avoids drug infusion and possible organ injury, allows for antidote recycling, and provides advantages for storage and handling of the antidote. Here we have developed Ngb-H64Q-CCC covalently bound to N-hydroxysuccinimide agarose. The immobilized protein shows preserved heme redox activity and retains its CO removal capacity after successive regeneration cycles. We expect that this novel approach will advance the development of new scavenger-based therapies for CO poisoning.
- Open Access
Immobilized neuroglobin scavenges carbon monoxide from circulating carboxyhemoglobin
Carbon monoxide (CO) poisoning is responsible for around 50,000 emergency department visits per year in the U.S. alone. With the present standard of care, persistent neurological sequelae occur in ∼30-40% of severe CO poisoning cases. Currently, there is no available targeted molecular antidote for CO poisoning. In previous work, we have developed an antidotal therapy for CO poisoning based on an engineered hemeprotein, human neuroglobin (Ngb-H64Q-CCC). Intravenous infusion of Ngb-H64Q-CCC removes CO from the circulating red blood cells and improves survival in a lethal CO-poisoning mouse model. However, the infusion of heme-containing proteins has inherent heme toxicity risks that may limit the dose that can be used safely without liver or kidney toxicity. In order to overcome these problems, we have investigated the development of immobilized Ngb in a solid matrix. This approach allows for the development of a CO removal system using an extracorporeal blood circulating system coupled with a stationary matrix with immobilized Ngb-H64Q-CCC. Such system avoids drug infusion and possible organ injury, allows for antidote recycling, and provides advantages for storage and handling of the antidote. By assessing the efficacy of Ngb-H64Q-CCC immobilized through different linkage strategies, we have identified N-hydroxysuccinimide agarose resin as a viable stationary phase. The immobilized protein shows preserved heme redox activity, can be chemically reduced/oxidized for activation/CO release purposes, and retains its CO removal capacity after successive regeneration cycles. We expect that this novel approach will advance the development of new scavenger-based therapies for CO poisoning.
Open AccessImmobilized neuroglobin scavenges carbon monoxide from circulating carboxyhemoglobin
Carbon monoxide (CO) poisoning is responsible for around 50,000 emergency department visits per year in the U.S. alone. With the present standard of care, persistent neurological sequelae occur in ∼30-40% of severe CO poisoning cases. Currently, there is no available targeted molecular antidote for CO poisoning. In previous work, we have developed an antidotal therapy for CO poisoning based on an engineered hemeprotein, human neuroglobin (Ngb-H64Q-CCC). Intravenous infusion of Ngb-H64Q-CCC removes CO from the circulating red blood cells and improves survival in a lethal CO-poisoning mouse model. However, the infusion of heme-containing proteins has inherent heme toxicity risks that may limit the dose that can be used safely without liver or kidney toxicity. In order to overcome these problems, we have investigated the development of immobilized Ngb in a solid matrix. This approach allows for the development of a CO removal system using an extracorporeal blood circulating system coupled with a stationary matrix with immobilized Ngb-H64Q-CCC. Such system avoids drug infusion and possible organ injury, allows for antidote recycling, and provides advantages for storage and handling of the antidote. By assessing the efficacy of Ngb-H64Q-CCC immobilized through different linkage strategies, we have identified N-hydroxysuccinimide agarose resin as a viable stationary phase. The immobilized protein shows preserved heme redox activity, can be chemically reduced/oxidized for activation/CO release purposes, and retains its CO removal capacity after successive regeneration cycles. We expect that this novel approach will advance the development of new scavenger-based therapies for CO poisoning.
- Open Access
- 18 February 2026
- Published by Elsevier in SSRN Electronic Journal
Sensitive and specific methodology for detection of labile NO-ferroheme complexes in vitro and in blood
Nitric oxide (NO) is formed via the oxidation of L-arginine in a reaction catalyzed by the NO synthase enzymes or via reduction of inorganic nitrite (NO2–) by deoxygenated hemoproteins and molybdopterin enzymes. We have recently demonstrated that NO can form a stable, labile ferrous heme-nitrosyl complex (NO-ferroheme) that protects NO from scavenging reactions in blood and has potent vasodilatory and platelet signaling activity. To enable future in vivo and in vitro studies establishing physiological NO-ferroheme formation, transport, and signaling, accurate and sensitive detection methods specifically for NO-ferroheme in biological milieu must be developed and validated. NO-heme complexes can be oxidized to release NO into the gas-phase for ozone-based chemiluminescence detection, which has been used for detection of iron-nitrosylated hemoglobin. In the current studies, we extend classical assays such as acidic potassium triiodide – with and without acidified sulfanilamide (AS) pre-treatment to eliminate NO2– and mercury(II) chloride (HgCl2) pretreatment to eliminate S-nitrosothiols – to detect and quantify NO-ferroheme, S-nitrosothiols, and nitrite. We also developed a new potassium ferricyanide/cyanide-based assay for sensitive and specific NO-ferroheme detection. All assays are sensitive and specific for NO-ferroheme to concentrations as low as 5 nM, with validated detection in buffer, plasma, whole blood and in vivo studies in mice. Additionally, we detect and quantify in vivo plasma NO-ferroheme formation and levels in mice after treatment with lipopolysaccharide (LPS), modeling pathological sepsis. These studies validate highly sensitive and specific assays for NO-ferroheme quantification and for the first time demonstrate plasma NO-ferroheme formation in vivo in a sepsis model.
- 18 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSensitive and specific methodology for detection of labile NO-ferroheme complexes in vitro and in blood
Nitric oxide (NO) is formed via the oxidation of L-arginine in a reaction catalyzed by the NO synthase enzymes or via reduction of inorganic nitrite (NO2–) by deoxygenated hemoproteins and molybdopterin enzymes. We have recently demonstrated that NO can form a stable, labile ferrous heme-nitrosyl complex (NO-ferroheme) that protects NO from scavenging reactions in blood and has potent vasodilatory and platelet signaling activity. To enable future in vivo and in vitro studies establishing physiological NO-ferroheme formation, transport, and signaling, accurate and sensitive detection methods specifically for NO-ferroheme in biological milieu must be developed and validated. NO-heme complexes can be oxidized to release NO into the gas-phase for ozone-based chemiluminescence detection, which has been used for detection of iron-nitrosylated hemoglobin. In the current studies, we extend classical assays such as acidic potassium triiodide – with and without acidified sulfanilamide (AS) pre-treatment to eliminate NO2– and mercury(II) chloride (HgCl2) pretreatment to eliminate S-nitrosothiols – to detect and quantify NO-ferroheme, S-nitrosothiols, and nitrite. We also developed a new potassium ferricyanide/cyanide-based assay for sensitive and specific NO-ferroheme detection. All assays are sensitive and specific for NO-ferroheme to concentrations as low as 5 nM, with validated detection in buffer, plasma, whole blood and in vivo studies in mice. Additionally, we detect and quantify in vivo plasma NO-ferroheme formation and levels in mice after treatment with lipopolysaccharide (LPS), modeling pathological sepsis. These studies validate highly sensitive and specific assays for NO-ferroheme quantification and for the first time demonstrate plasma NO-ferroheme formation in vivo in a sepsis model.
- 12 September 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 65 (3) , 374-389
Artificial Oxygen Carriers: Lessons From Hemoglobin-Based Oxygen Carrier Clinical Trials and Current Development Efforts
The clinical benefit of blood transfusion is undeniable, and yet reliance on donated blood products has several shortcomings. These include risks of supply shortages due to reliance on volunteer donors, short storage life, and potential infectious disease transmission. Immune response complications to donated blood cannot be completely avoided, despite significant advances in testing. Many of these limitations are exacerbated in low-income countries. For decades, cell-free hemoglobin-based blood substitutes have been developed and tested as potential substitutes for red blood cell transfusions. Early studies found that purified, native hemoglobin exhibited significant safety risks, such as hypertension from excessive vasoconstriction and evidence of multiple organ toxicities. These effects are likely in part due to the reactive heme center, which will scavenge nitric oxide, generate reactive oxygen species, and may drive sterile inflammation. Numerous strategies have been explored to further modify hemoglobin in the hope of creating a safe and well-tolerated blood substitute. Despite some promising results in preliminary studies, large-scale clinical trials have continued to show elevated rates of adverse events and/or a failure to meet specified clinical endpoints. As a result, no hemoglobin-based oxygen carrier (HBOC) has obtained US Food and Drug Administration approval for clinical use. This review focuses on the history of HBOC development, the lessons that have been learned from prior failures of HBOC programs, and the status of ongoing artificial oxygen carrier development efforts.
- 12 September 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 65 (3) , 374-389
Artificial Oxygen Carriers: Lessons From Hemoglobin-Based Oxygen Carrier Clinical Trials and Current Development Efforts
The clinical benefit of blood transfusion is undeniable, and yet reliance on donated blood products has several shortcomings. These include risks of supply shortages due to reliance on volunteer donors, short storage life, and potential infectious disease transmission. Immune response complications to donated blood cannot be completely avoided, despite significant advances in testing. Many of these limitations are exacerbated in low-income countries. For decades, cell-free hemoglobin-based blood substitutes have been developed and tested as potential substitutes for red blood cell transfusions. Early studies found that purified, native hemoglobin exhibited significant safety risks, such as hypertension from excessive vasoconstriction and evidence of multiple organ toxicities. These effects are likely in part due to the reactive heme center, which will scavenge nitric oxide, generate reactive oxygen species, and may drive sterile inflammation. Numerous strategies have been explored to further modify hemoglobin in the hope of creating a safe and well-tolerated blood substitute. Despite some promising results in preliminary studies, large-scale clinical trials have continued to show elevated rates of adverse events and/or a failure to meet specified clinical endpoints. As a result, no hemoglobin-based oxygen carrier (HBOC) has obtained US Food and Drug Administration approval for clinical use. This review focuses on the history of HBOC development, the lessons that have been learned from prior failures of HBOC programs, and the status of ongoing artificial oxygen carrier development efforts.
- Open Access
Cytochrome b5 reductase 4 efficiently reduces Neuroglobin and Cytoglobin
Cytoglobin and Neuroglobin are heme-containing proteins expressed in most vertebrates, including mammals, with still not completely defined physiological roles. Most of the putative functions of cytoglobin/neuroglobin, such as oxygen binding or nitric oxide dioxygenation, rely on the heme iron being in the ferrous (Fe2+) oxidation state. Therefore, it is very possible that reducing systems are active in the cell to maintain both proteins in the ferrous state. We have previously shown that the cytochrome b5 reductase isoform 3/ cytochrome b5 system, the canonical reductase of hemoglobin and myoglobin, can reduce cytoglobin at very fast rates, consistent with a possible physiological role. However this reducing system is unable to reduce neuroglobin, which to date lacks a validated, physiologically feasible reducing system. Here we have studied the interaction of cytochrome b5 reductase isoform 4 with cytoglobin and neuroglobin and found that cytochrome b5 reductase 4 can reduce cytoglobin at rates comparable to those observed with cytochrome b5 reductase 3/ cytochrome b5. Remarkably, it can also reduce neuroglobin efficiently. Studying different surface mutations of cytoglobin and neuroglobin we note that some cytoglobin mutations, in particular R84E and K116E decrease reduction rates by more than 10-fold, whereas surface mutations in neuroglobin that were shown to impair the interaction of neuroglobin with cytochrome c (E60K/D73K/E87K) show little effect on the reduction rates. We conclude that cytochrome b5 reductase 4 can supplement cytochrome b5 reductase 3/ cytochrome b5 roles for cytoglobin reduction in vivo and is a strong candidate for a physiological role as neuroglobin reductase.
Open AccessCytochrome b5 reductase 4 efficiently reduces Neuroglobin and Cytoglobin
Cytoglobin and Neuroglobin are heme-containing proteins expressed in most vertebrates, including mammals, with still not completely defined physiological roles. Most of the putative functions of cytoglobin/neuroglobin, such as oxygen binding or nitric oxide dioxygenation, rely on the heme iron being in the ferrous (Fe2+) oxidation state. Therefore, it is very possible that reducing systems are active in the cell to maintain both proteins in the ferrous state. We have previously shown that the cytochrome b5 reductase isoform 3/ cytochrome b5 system, the canonical reductase of hemoglobin and myoglobin, can reduce cytoglobin at very fast rates, consistent with a possible physiological role. However this reducing system is unable to reduce neuroglobin, which to date lacks a validated, physiologically feasible reducing system. Here we have studied the interaction of cytochrome b5 reductase isoform 4 with cytoglobin and neuroglobin and found that cytochrome b5 reductase 4 can reduce cytoglobin at rates comparable to those observed with cytochrome b5 reductase 3/ cytochrome b5. Remarkably, it can also reduce neuroglobin efficiently. Studying different surface mutations of cytoglobin and neuroglobin we note that some cytoglobin mutations, in particular R84E and K116E decrease reduction rates by more than 10-fold, whereas surface mutations in neuroglobin that were shown to impair the interaction of neuroglobin with cytochrome c (E60K/D73K/E87K) show little effect on the reduction rates. We conclude that cytochrome b5 reductase 4 can supplement cytochrome b5 reductase 3/ cytochrome b5 roles for cytoglobin reduction in vivo and is a strong candidate for a physiological role as neuroglobin reductase.
- Open Access
- 28 June 2025
- Published by Wolters Kluwer Health in Medical Gas Research
- Vol. 16 (1) , 90-91
Combined carbon monoxide poisoning and smoke inhalational injury in a case of severe underlying lung disease
- 28 June 2025
- Published by Wolters Kluwer Health in Medical Gas Research
- Vol. 16 (1) , 90-91
Open AccessCombined carbon monoxide poisoning and smoke inhalational injury in a case of severe underlying lung disease
- Open Access
Engineering a highly selective, hemoprotein-based scavenger as a carbon monoxide poisoning antidote with no hypertensive effect
Carbon monoxide (CO) poisoning causes 50,000-100,000 emergency department visits and ∼1,500 deaths in the United States annually. Current treatments are limited to supplemental and/or hyperbaric oxygen to accelerate CO elimination. Even with oxygen therapy, nearly half of CO poisoning survivors suffer long-term cardiac and neurocognitive deficits related to slow CO clearance, highlighting a need for point of care antidotal therapies. Given the natural interaction between CO and ferrous heme, we hypothesized that the hemoprotein RcoM, a transcriptional regulator of microbial CO metabolism, would make an ideal platform for CO-selective scavenging from endogenous hemoproteins. We engineered an RcoM truncate (RcoM-HBD-CCC) that exhibits high CO affinity ( K a,CO = 2.8×10 10 M -1 ), remarkable selectivity for CO over oxygen ( K a,O2 = 1.4×10 5 M -1 ; K a,CO / K a,O2 = 1.9×10 5 ), thermal stability (T m = 72°C), slow autoxidation rate ( k ox = 1.1 h -1 ). In a murine model of acute CO poisoning, infused RcoM-HBD-CCC accelerated CO clearance from hemoglobin in red blood cells and was rapidly excreted in urine. Moreover, infused RcoM-HBD-CCC elicited minimal hypertension in mice compared to infused hemoglobin, attributed to a comparatively limited reactivity toward nitric oxide (NO) via dioxygenation ( k NOD (RcoM) = 6-8×10 6 M -1 s -1 vs k NOD (Hb) = 6-8×10 7 M -1 s -1 ). These data suggest that RcoM-HBD-CCC is a safe, selective, and efficacious CO scavenger. Additionally, by limiting hypertension RcoM-HBD-CCC improves end-organ adverse effects compared with hemoglobin-based therapeutics.
Open AccessEngineering a highly selective, hemoprotein-based scavenger as a carbon monoxide poisoning antidote with no hypertensive effect
Carbon monoxide (CO) poisoning causes 50,000-100,000 emergency department visits and ∼1,500 deaths in the United States annually. Current treatments are limited to supplemental and/or hyperbaric oxygen to accelerate CO elimination. Even with oxygen therapy, nearly half of CO poisoning survivors suffer long-term cardiac and neurocognitive deficits related to slow CO clearance, highlighting a need for point of care antidotal therapies. Given the natural interaction between CO and ferrous heme, we hypothesized that the hemoprotein RcoM, a transcriptional regulator of microbial CO metabolism, would make an ideal platform for CO-selective scavenging from endogenous hemoproteins. We engineered an RcoM truncate (RcoM-HBD-CCC) that exhibits high CO affinity ( K a,CO = 2.8×10 10 M -1 ), remarkable selectivity for CO over oxygen ( K a,O2 = 1.4×10 5 M -1 ; K a,CO / K a,O2 = 1.9×10 5 ), thermal stability (T m = 72°C), slow autoxidation rate ( k ox = 1.1 h -1 ). In a murine model of acute CO poisoning, infused RcoM-HBD-CCC accelerated CO clearance from hemoglobin in red blood cells and was rapidly excreted in urine. Moreover, infused RcoM-HBD-CCC elicited minimal hypertension in mice compared to infused hemoglobin, attributed to a comparatively limited reactivity toward nitric oxide (NO) via dioxygenation ( k NOD (RcoM) = 6-8×10 6 M -1 s -1 vs k NOD (Hb) = 6-8×10 7 M -1 s -1 ). These data suggest that RcoM-HBD-CCC is a safe, selective, and efficacious CO scavenger. Additionally, by limiting hypertension RcoM-HBD-CCC improves end-organ adverse effects compared with hemoglobin-based therapeutics.
- Open Access
- 29 January 2024
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 75 (1) , 337-351
Carbon Monoxide Poisoning: From Microbes to Therapeutics
Carbon monoxide (CO) poisoning leads to 50,000–100,000 emergency room visits and 1,500–2,000 deaths each year in the United States alone. Even with treatment, survivors often suffer from long-term cardiac and neurocognitive deficits, highlighting a clear unmet medical need for novel therapeutic strategies that reduce morbidity and mortality associated with CO poisoning. This review examines the prevalence and impact of CO poisoning and pathophysiology in humans and highlights recent advances in therapeutic strategies that accelerate CO clearance and mitigate toxicity. We focus on recent developments of high-affinity molecules that take advantage of the uniquely strong interaction between CO and heme to selectively bind and sequester CO in preclinical models. These scavengers, which employ heme-binding scaffolds ranging from organic small molecules to hemoproteins derived from humans and potentially even microorganisms, show promise as field-deployable antidotes that may rapidly accelerate CO clearance and improve outcomes for survivors of acute CO poisoning.
- 29 January 2024
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 75 (1) , 337-351
Open AccessCarbon Monoxide Poisoning: From Microbes to Therapeutics
Carbon monoxide (CO) poisoning leads to 50,000–100,000 emergency room visits and 1,500–2,000 deaths each year in the United States alone. Even with treatment, survivors often suffer from long-term cardiac and neurocognitive deficits, highlighting a clear unmet medical need for novel therapeutic strategies that reduce morbidity and mortality associated with CO poisoning. This review examines the prevalence and impact of CO poisoning and pathophysiology in humans and highlights recent advances in therapeutic strategies that accelerate CO clearance and mitigate toxicity. We focus on recent developments of high-affinity molecules that take advantage of the uniquely strong interaction between CO and heme to selectively bind and sequester CO in preclinical models. These scavengers, which employ heme-binding scaffolds ranging from organic small molecules to hemoproteins derived from humans and potentially even microorganisms, show promise as field-deployable antidotes that may rapidly accelerate CO clearance and improve outcomes for survivors of acute CO poisoning.
- 3 July 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (7) , 492-499
Heart-Brain 346-7 Score: the development and validation of a simple mortality prediction score for carbon monoxide poisoning utilizing deep learning
- 3 July 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (7) , 492-499
Heart-Brain 346-7 Score: the development and validation of a simple mortality prediction score for carbon monoxide poisoning utilizing deep learning